MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?

Not Applicable
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2010-06-28
Last Posted Date
2011-04-28
Lead Sponsor
Ziv Hospital
Target Recruit Count
60
Registration Number
NCT01151397
Locations
🇮🇱

Ziv medical center liver unit, Safed, Israel, Israel

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

Phase 3
Completed
Conditions
Chronic Hepatitis
Interventions
First Posted Date
2010-05-12
Last Posted Date
2011-08-10
Lead Sponsor
Casa Sollievo della Sofferenza IRCCS
Target Recruit Count
360
Registration Number
NCT01121705
Locations
🇮🇹

Ospedale Civile, Sassari, Italy

🇮🇹

Ospedale Casarano, Casarano, Italy

🇮🇹

Ospedale "Garibaldi", Catania, Italy

and more 4 locations

Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy

Not Applicable
Conditions
Bowel Preparation
Interventions
First Posted Date
2010-03-25
Last Posted Date
2010-03-25
Lead Sponsor
Rabin Medical Center
Target Recruit Count
200
Registration Number
NCT01093274
Locations
🇮🇱

Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Phase 2
Completed
Conditions
Hepatitis C
Interventions
First Posted Date
2010-01-22
Last Posted Date
2014-04-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
64
Registration Number
NCT01054729
Locations
🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

Alamo Medical Research Center, San Antonio, Texas, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

and more 4 locations

A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy

Not Applicable
Conditions
Bowel Preparation for Colonoscopy
Interventions
First Posted Date
2009-12-09
Last Posted Date
2012-03-14
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
400
Registration Number
NCT01028573
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, California, United States

A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy

First Posted Date
2009-08-06
Last Posted Date
2012-11-30
Lead Sponsor
Brooke Army Medical Center
Target Recruit Count
425
Registration Number
NCT00953017
Locations
🇺🇸

Brooke Army Medical Center, San Antonio, Texas, United States

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

First Posted Date
2009-04-29
Last Posted Date
2009-04-29
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
432
Registration Number
NCT00889655
Locations
🇺🇸

Oregon Health & Sciences University, Portland, Oregon, United States

Effects of Oral PEG 3350 on Electrolyte Balance

Phase 1
Completed
Conditions
Chronic Constipation
Interventions
First Posted Date
2009-03-25
Last Posted Date
2009-03-25
Lead Sponsor
Norgine
Target Recruit Count
114
Registration Number
NCT00868985
Locations
🇷🇴

IFE Human Pharmacology, Timisoara, Romania

F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects

First Posted Date
2009-03-06
Last Posted Date
2010-10-05
Lead Sponsor
Braintree Laboratories
Target Recruit Count
308
Registration Number
NCT00857272
Locations
🇺🇸

Advanced Clinical Research Institute, Orange, California, United States

🇺🇸

Medical Associates Research Group, San Diego, California, United States

🇺🇸

Franklin Gastroenterology, Franklin, Tennessee, United States

and more 2 locations

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Phase 2
Completed
Conditions
Adenomatous Polyp
Colorectal Carcinoma
Interventions
Other: Placebo
Other: Laboratory Biomarker Analysis
First Posted Date
2009-01-26
Last Posted Date
2017-04-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
87
Registration Number
NCT00828984
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath